Istvan Molnar, M.D. serves as Chief Medical Officer, bringing 15 years of oncology clinical development experience, including significant expertise in radiopharmaceutical clinical development. Prior to joining Radionetics, he was Chief Medical Officer at Lantheus Medical Imaging and at Fusion Pharmaceuticals. Previous to these appointments, Dr. Molnar was Vice President of Clinical Development at Merrimack Pharmaceuticals and Director and Global Clinical Lead at Bayer Pharmaceuticals. He has accumulated considerable experience in all stages of oncology drug development, encompassing several successful drug approvals with significant time spent on radiopharmaceutical projects at Bayer, Fusion Pharmaceuticals and Lantheus Medical Imaging including radium-223 dichloride (Xofigo®) and piflufolastat F 18 (Pylarify®) for prostate cancer. Prior to his industry career, he was Assistant Professor at Wake Forest University. Dr. Molnar obtained his medical degree at Semmelweis University in Budapest, Hungary and completed an internal medicine residency at Meridia Huron Hospital in Ohio and a Hematology-Oncology Fellowship at Wake Forest University School of Medicine in North Carolina.